Radiolabel, LC-MS/MS or Fluorescence — Choosing a Detection Method for Vesicular Transport Assays
The transporter assay is the same in all three cases. What differs is how you measure what ended up inside the vesicle — and that choice determines throughput, infrastructure and whether a regulator will accept the number.
What all three have in common
The biology is identical. Only the readout changes.
In every case you incubate inverted membrane vesicles with a probe substrate, once in the presence of ATP and once with AMP. The ATP-dependent fraction — the difference between the two — is genuine transport. Vesicles are then captured on a filter, washed, and whatever accumulated inside is quantified.
The detection method is that last step. It does not change the transport biology, but it changes what you can measure, how many compounds per day, and what equipment the work requires.
The three methods
Radiolabel
A ³H- or ¹⁴C-labelled probe substrate. Accumulated radioactivity is measured by scintillation counting.
Very sensitive, very low background, and the format behind most of the published reference data.
LC-MS/MS
Unlabelled substrate, quantified by chromatography and mass spectrometry after the vesicles are lysed.
The only method that can measure your test compound itself rather than its effect on a probe.
Fluorescence
A fluorescent probe substrate, read on a standard plate reader.
Fastest and cheapest, with no special licence — but constrained by which transporters have a usable probe.
Side by side
| Radiolabel | LC-MS/MS | Fluorescence | |
|---|---|---|---|
| Sensitivity | Very high | High | Moderate |
| Throughput | Moderate | Lower — run time per sample | High |
| Measures the test compound itself | Only if labelled | Yes | No |
| Method development per compound | None | Required | None |
| Infrastructure | Radiochemistry licence, dedicated area, scintillation counter | LC-MS/MS instrument | Plate reader |
| Waste handling | Radioactive waste | Standard solvent | Standard |
| Interference risk | Low | Matrix effects, ion suppression | Autofluorescence, quenching |
| Regulatory standing | Reference method | Accepted | Supporting evidence |
Radiolabel — the reference, with a facility requirement
If you already handle radioactivity, this is usually the straightforward answer.
Radiolabelled probe substrates are well established for the efflux transporters, and the reference values in the literature were largely generated this way. That matters more than it sounds: when a reviewer compares your IC50 against published data for the same transporter, comparability of method removes one line of questioning.
Typical probe substrates in the vesicular format:
| Transporter | Common probe substrate |
|---|---|
| BSEP | Taurocholate |
| BCRP | Estrone-3-sulfate |
| MRP1, MRP2, MRP3 | Estradiol-17β-glucuronide |
| MRP4 | DHEAS or cyclic nucleotides |
| P-gp | N-methylquinidine |
Kit-specific substrates and recommended concentrations come from the datasheet — treat the table above as orientation, not as an assay protocol.
LC-MS/MS — when you need the compound itself
The only format in which the analyte can be your molecule rather than a surrogate.
That single property answers questions the other two cannot:
- Is my compound a substrate? Quantify how much of it accumulated in the vesicle, ATP-dependently.
- Metabolite work. Metabolites are rarely available labelled and almost never fluorescent — but they are routinely measurable by mass spectrometry.
- No radiochemistry facility. For many laboratories this is the deciding factor, and it is a legitimate one.
The price is method development. Every new compound needs a transition, a calibration and a check for matrix effects before the assay can run. For a single compound that is a day; for a screening cascade it becomes the bottleneck.
Fluorescence — fast, cheap, narrower
Right for triage, wrong as the only evidence in a submission.
A plate reader, no licence, no method development, and results in minutes. For ranking a compound series or triaging a library before committing to a definitive method, that combination is hard to beat.
Three constraints:
- Not every transporter has a usable fluorescent probe. Coverage is decent for some, absent for others.
- The probe is a different molecule. A transporter may handle a fluorophore-tagged substrate differently from a physiological one, so absolute values do not always transfer between detection methods.
- Compound interference. Autofluorescence and quenching are common with drug-like molecules, and both produce results that look like transport effects but are not.
How to decide
| Your situation | Method |
|---|---|
| IC50 for a DDI submission | Radiolabel, or LC-MS/MS |
| No radiochemistry facility | LC-MS/MS |
| Is my compound a substrate? | LC-MS/MS, or a cell-based assay |
| Metabolites | LC-MS/MS |
| Screening a large series | Fluorescence, confirm hits by another method |
| Comparing against published reference values | Radiolabel |
| Compound is coloured or autofluorescent | Not fluorescence |
Most well-designed cascades use two: a fast method for triage and a defensible one for the compounds that survive it.
What stays the same regardless of method
- Control vesicles in every run. ATP-dependent transport is the difference between transporter vesicles and non-transfected controls — see the Human Control Vesicle Kit.
- AMP as the negative condition, not ATP omission — it keeps the ionic environment comparable.
- Lot-specific transport ratios. A low ATP/AMP ratio compresses the assay window and inflates variability, whatever you measure with.
- The expression system. Glycosylation and membrane lipid composition differ by host cell — covered in HEK293 vs. Sf9 vesicles.
Frequently asked questions
Which detection method do regulators expect?
ICH M12 does not prescribe one. In practice, IC50 values submitted for efflux transporter DDI assessment come predominantly from radiolabel or LC-MS/MS. Fluorescence data typically appears as supporting evidence rather than as the primary determination.
Can I run vesicular assays without a radiochemistry licence?
Yes. LC-MS/MS and fluorescence both avoid radioactivity entirely. LC-MS/MS is the option that remains defensible for regulatory work.
Why can radiolabel not tell me whether my compound is a substrate?
Because the label is on the probe, not on your compound. You are measuring how your compound affects transport of something else. To see whether your molecule is itself transported, it has to be the analyte — which means LC-MS/MS or a custom label.
My compound is fluorescent. Can I still use a fluorescence assay?
Only with caution, and only after a compound-only control confirms it does not interfere with the readout. In most such cases switching method is faster than validating around the problem.
Do the three methods give the same IC50?
Usually the same order of magnitude, not always the same number. Different probe substrates interact with the transporter differently. Where values matter, keep the method consistent within a project and state it in the report.
Are Cell4Pharma vesicle kits compatible with all three?
Yes — the vesicles are the same regardless of readout. Which probe substrate and concentration to use depends on the transporter; the datasheet gives the validated conditions for each kit.
Related
Kits that work with whichever readout you have
Cell4Pharma vesicle kits from EU stock — compatible with radiolabel, LC-MS/MS and fluorescence detection. Tell us your transporter and your instrumentation and we will confirm the conditions.
Request a quote
English 
Deutsch